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Abstract 
Introduction 
Multiple myeloma (MM) is a disease characterised by the neoplastic prolifera-
tion of plasma cells in the bone marrow. Daratumumab (Darzalex
®
) is a hu-
man monoclonal IgG1κ antibody directed against CD38, which is approved 
by the European Medicines Agency (EMA) and the US Food and Drug Ad-
ministration (FDA) as a monotherapy or in combination regimens for pa-
tients with MM who received prior lines of therapy. In May 2018, the FDA 
approved daratumumab in combination with bortezomib, melphalan and 
prednisone for the treatment of patients with newly diagnosed MM who are 
ineligible for autologous stem-cell transplantation (ASCT). 
Methodology 
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer, resulting in 137 references overall. A quality 
assessment was conducted to assess the risk of bias at the study level based 
on the EUnetHTA internal validity for randomised controlled trials. The 
magnitude of clinically meaningful benefit that can be expected from a new 
anti-cancer treatment based on the Magnitude of Clinical Benefit Scale de-
veloped by the European Society for Medical Oncology has not been applied 
since it can only be used for solid tumours. 
Results from ALCYONE trial 
The ALCYONE trial assessed the efficacy and safety of the addition of 
daratumumab to bortezomib, melphalan and prednisone in patients with 
newly diagnosed MM who were ineligible for high-dose chemotherapy 
with stem-cell transplantation (SCT). A total of 706 patients were enrolled 
and received either nine cycles of bortezomib, melphalan and prednisone 
alone or in combination with daratumumab until disease progression. 
Analyses showed that patients of the daratumumab group had a lower risk 
of disease progression or death than patients of the control group: hazard 
ratio was 0.50 (95% CI, 0.38–0.65; p < 0.001). The 12-month rate and the 
18-month rate of progression-free survival (PFS) were prolonged in pa-
tients receiving daratumumab (86.7% and 71.6% respectively) compared 
to control group patients (76.0% and 50.2% respectively). The overall re-
sponse rate was higher in the daratumumab group (90.9%) than in the 
control group (73.9%). The median OS was not reached in either group. 
The most frequent adverse events (AEs) of grade 3 or 4 were neutropenia, 
thrombocytopenia and anaemia, occurring in 39.9%, 34.4% and 15.9% of 
daratumumab group patients and in 38.7%, 37.6% and 19.8% of control 
group patients respectively. The rate of serious AEs was higher in patients 
receiving daratumumab (41.6%) than in control group patients (32.5%).  
Conclusion 
The addition of daratumumab to the standard combination treatment of 
bortezomib, melphalan and prednisone in untreated MM patients resulted 
in a statistically significant benefit with a lower risk of disease progression 
or death, prolongation of PFS across all subgroups and a higher rate of nega-
tive status for MRD. These benefits need to be weighed against higher rates 
of infections and the occurrence of infusion-related reactions among patients 
receiving daratumumab. Furthermore, the costs for a four-drug regimen and 
the required concurrent medication have to be considered. Since no further 
valid OS data can be expected and quality of life (QoL) data is lacking, the 
clinical benefit of the assessed intervention remains to be proven.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to predefined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is daratumumab? 
A0022 Who manufactures daratumumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has daratumumab received marketing authorisation? 
Health problem and current use 
A0002 What is multiple myeloma? 
A0004 What is the natural course of multiple myeloma? 
A0006 What are the consequences of multiple myeloma for the society? 
A0023 How many people belong to the target population? 
 
A0005 What are the symptoms and the burden of multiple myeloma? 
A0003 What are the known risk factors for multiple myeloma? 
A0024 
How is multiple myeloma currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is multiple myeloma currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of daratumumab on mortality? 
D0006 How does daratumumab affect progression (or recurrence) of multiple myeloma? 
D0005 
How does daratumumab affect symptoms and findings (severity, frequency) of multiple 
myeloma? 
D0011 What is the effect of daratumumab on patients ̕  body functions? 
D0012 What is the effect of daratumumab on generic health-related quality of life? 
D0013 What is the effect of daratumumab on disease-specific quality of life? 
Safety 
C0008 How safe is daratumumab in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying daratumumab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of daratumumab? 
A0021 What is the reimbursement status of daratumumab? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Daratumumab/Darzalex
®
/L01XC24 
 
B0001: What is daratumumab? 
Daratumumab (Darzalex
®
) is a human monoclonal IgG1κ antibody directed 
against CD38. CD38 is a cell surface glycoprotein which is present on vari-
ous immune cells and regulates the cytotoxic response of activated natural 
killer cells. Daratumumab is produced in a mammalian cell line (Chinese 
hamster ovary) using recombinant deoxyribonucleic acid (DNA) technology. 
The binding of daratumumab to natural killer cells simulates the normal 
CD38-CD31 interaction that proceeds on the surface of these cells. As CD38 
is also present on multiple myeloma (MM) cells and plasma leukaemia cells, 
daratumumab may preferentially bind to these cells, thereby triggering anti-
tumoural antibody-dependent cellular cytotoxicity and complement-
dependent cytotoxicity [2, 3]. 
The recommended dose of daratumumab for monotherapy and in combina-
tion with lenalidomide (4-week-cycle regimen) is an intravenous (IV) admin-
istration of 16 mg/kg of body weight weekly (total of eight doses) on weeks 1 
to 8, every two weeks (total of eight doses) on weeks 9 to 24 and every four 
weeks from week 25 onwards until disease progression. For combination 
therapy with bortezomib (3-week-cycle regimen), a modified dosing sched-
ule is recommended: 16 mg/kg of body weight (IV) weekly on weeks 1 to 9 
(total of nine doses), every three weeks (total of five doses) on weeks 10 to 24 
and every four weeks from week 25 onwards until disease progression [2]. 
To reduce the risk of infusion-related reactions (IRRs) with daratumumab, 
pre- and post-infusion medication should be administered. All patients 
should receive pre-infusion medication one to three hours prior to every 
daratumumab infusion, including [2]: 
 A corticosteroid: 
- Monotherapy: methylprednisone 100 mg (IV) or 
equivalent, the dose may be reduced following the sec-
ond infusion 
- Combination therapy: dexamethasone 20 mg (IV) pri-
or to the first daratumumab infusion, oral administra-
tion may be considered prior to subsequent infusions 
 Antipyretics: oral paracetamol, 650 to 1,000 mg 
 Antihistamine: oral or IV diphenhydramine, 25 to 50 mg or equiva-
lent. 
To reduce the risk of delayed IRRs, post-infusion medication should be ad-
ministered [2]: 
 Monotherapy: oral corticosteroid (methylprednisolone) 
20 mg or equivalent on each of the two days following all 
infusions 
 Combination therapy: low-dose oral methylprednisolone 
(≤ 20 mg) or equivalent should be considered on the day 
after the daratumumab infusion. 
human monoclonal 
antibody directed 
against CD38 
16 mg/kg of body 
weight administered IV, 
different dosing 
regimens for mono- and 
combination therapy 
pre- and post-infusion 
medication to reduce 
the risk of IRR 
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In addition, for patients with a history of chronic obstructive pulmonary 
disease, the use of short- and long-acting bronchodilators and inhaled corti-
costeroids after daratumumab infusions should be considered. Also, preven-
tion for a herpes zoster virus reactivation should be taken into consideration 
[2].  
 
A0022: Who manufactures daratumumab? 
Janssen Biologics B.V. 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Daratumumab is indicated in patients with newly diagnosed MM who are 
not eligible for high-dose chemotherapy with stem-cell transplantation 
(SCT). 
 
 
 
4 Current regulatory status 
A0020: For which indications has daratumumab received marketing author-
isation? 
To date, the use of daratumumab in combination with standard treatment in 
patients with newly diagnosed MM is not approved by the European Medi-
cines Agency (EMA). 
The EMA approved daratumumab (Darzalex
®
) for the following indications 
[4]: 
 Orphan designation was granted for the treatment of plasma-cell 
myeloma in July 2017 
 As monotherapy for the treatment of adult patients with relapsed 
and refractory MM, whose prior therapy included a proteasome in-
hibitor (PI) and an immunomodulatory agent, and who have 
demonstrated disease progression on the last therapy (approved in 
May 2016) 
 In combination with lenalidomide and dexamethasone, or borte-
zomib and dexamethasone, for the treatment of adult patients with 
MM who have received at least one prior therapy (approved in Feb-
ruary 2017). 
short- and long-acting 
bronchodilators for 
patients with a history 
of chronic obstructive 
pulmonary disease 
patients with untreated 
MM, ineligible for SCT  
currently not approved 
for untreated MM 
approved indications in 
Europe 
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In May 2018, the FDA granted marketing authorisation for daratumumab 
(Darzalex
TM
) in combination with bortezomib, melphalan and prednisone 
for the treatment of patients with newly diagnosed MM who are ineligible 
for autologous stem-cell transplantation (ASCT). The following further in-
dications are approved in the US [5]: 
 Patients with MM who have received at least three prior lines of 
therapy including a PI and an immunomodulatory agent or who are 
double-refractory to a PI and an immunomodulatory agent (accel-
erated approval in November 2015) 
 Patients with MM who have received at least one prior therapy, in 
combination with lenalidomide and dexamethasone or bortezomib 
and dexamethasone (approved in November 2016) 
 Patients with MM who have received at least two prior therapies 
(including lenalidomide and a PI), in combination with pomalido-
mide and dexamethasone (approved in June 2016). 
 
 
 
5 Burden of disease 
A0002: What is multiple myeloma? 
MM is a disease characterised by the neoplastic proliferation of plasma cells in 
the bone marrow, often resulting in extensive skeletal destruction with osteo-
lytic lesions, osteopenia and/or pathologic fractures. The disease is thought to 
develop from a pre-malignant stage of clonal plasma cell proliferation termed 
as “monoclonal gammopathy of undetermined significance” (MGUS). MGUS, 
which is asymptomatic and present in over three percent of the population 
older than 50 years, appears to be the result of cytogenetic abnormalities. 
MGUS can progress to MM due to the following factors: additional genetic 
abnormalities, changes in the bone marrow microenvironment, an increased 
cell proliferation (because of cell-cycle dysregulation) or an evasion apoptosis. 
Some patients develop an intermediate asymptomatic but more advanced 
premalignant stage termed “smouldering multiple myeloma” (SMM) [6, 7]. 
The rate of progression of MGUS to MM is 1% per year; SMM progresses to 
MM at a rate of 10% per year over the first five years after diagnosis, then the 
rate declines to 3% per year over the following five years and to 1.5% per year 
thereafter [8]. 
 
A0004: What is the natural course of multiple myeloma? 
MM is a disease characterised by a highly variable course and a heterogene-
ous clinical behaviour [8]. Some patients progress rapidly despite treatment, 
whereas other patients do not require therapy for years. The prognosis of 
MM patients depends on staging, patient factors, disease biology, the availa-
bility of therapy and the response to therapy [9]. 
May 2018: FDA approval 
for daratumumab + 
bortezomib + melphalan 
+ prednisone 
MM: neoplastic 
proliferation of plasma 
cells in the bone marrow 
 
 
MGUS:  
pre-malignant stage 
highly variable course of 
disease 
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The 5-year relative survival rate
1
 of MM is 50.7%. In general, 5% of MM 
cases are diagnosed at a local stage with a 5-year survival rate of 72%. 95% of 
cases are diagnosed at a distant stage when cancer has already metastasised 
resulting in a 5-year survival rate of 49.6% [10]. 
 
A0006: What are the consequences of multiple myeloma for the society? 
A0023: How many people belong to the target population? 
In Austria, 409 persons per year (2015) are newly diagnosed with myeloma; 
the disease is more common in men (219 newly diagnosed men in 2015) than 
in women (190 newly diagnosed women in 2015). The age-standardised inci-
dence rate for the European Standard Population for myeloma (2015) is 5.8 
per 100,000 per year in men and 4.1 per 100,000 per year in women [11]. 
In Europe, the median age at diagnosis is 72 years [8]. Based on 2013 to 2015 
data from the US, approximately 0.8% of men and women will be diagnosed 
with myeloma at some point during their lifetime [10]. 
 
A0005: What are the symptoms and the burden of multiple myeloma? 
Patients develop symptoms once the clonal plasma cell population is created 
and progresses to MM, owing to the infiltration of plasma cells into the bone 
marrow or other organs, or due to kidney damage caused by excess light 
chains [6]. The most common symptoms include anaemia, bone pain, renal 
disease (elevated creatinine), hypercalcaemia, or neurologic disease with 
radiculopathy, which represents the most common neurologic complication 
of MM. Due to a combination of immune dysfunction and physical factors, 
there is an increased risk of infections in patients with MM. Less common 
symptoms are paraesthesia, hepatomegaly, splenomegaly, lymphadenopathy; 
pleural effusion and diffuse pulmonary involvement are rare and usually oc-
cur in patients with advanced disease). Approximately seven percent of MM 
patients have extramedullary plasmacytomas (EP) at the time of diagnosis, 
which is associated with inferior survival. EP develops later in the course of 
MM in an additional six percent of patients [7]. 
 
A0003: What are the known risk factors for multiple myeloma? 
MM is more common in men than women, with a higher incidence among 
persons of African American descent [7, 10]. In addition, the risk of develop-
ing MM increases with body mass index. Persons with a first-degree relative 
affected by MM have an approximately 3.7 times higher risk of developing 
the disease [7]. Furthermore, patients with a history of MGUS have a higher 
risk of developing MM [10]. Although the exact cause of MGUS is not en-
tirely clarified yet, epidemiologic data suggests potential risk factors include 
genetic predisposition, older age, immunosuppression, hormonal factors and 
environmental exposures [6]. 
 
                                                             
1
 The relative survival rate compares the survival of patients diagnosed with cancer 
with the survival of people in the general population who are the same age, race 
and sex and who have not been diagnosed with cancer. 
5-year relative survival 
rate: 50.7% 
MM incidence rate in 
Austria: 4.9/100,000 
persons per year 
median age at diagnosis: 
72 years 
most common 
symptoms: anaemia, 
bone pain, renal disease, 
hypercalcaemia, 
neurologic disease 
 
 
approximately 7% of 
patients have EP at the 
time of diagnosis 
higher risk: men, African 
Americans, history of 
MGUS, family history of 
MM 
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A0024: How is multiple myeloma currently diagnosed according to pub-
lished guidelines and in practice? 
According to the National Comprehensive Cancer Network (NCCN) [12], 
the initial MM diagnostic workup should include a medical history and 
physical examination. In addition, various assessments are recommended to 
differentiate symptomatic and asymptomatic MM: a complete blood count 
(with differential and platelet counts), examination of peripheral blood 
smear (to show abnormal distribution of red blood cells), blood urea nitro-
gen (BUN), serum creatinine (increased BUN and creatinine indicate de-
creased kidney function), creatinine clearance, serum electrolytes, serum 
calcium, albumin, lactate dehydrogenase (LDH) and beta-2 microglobulin.  
Serum and urine analyses should be conducted to evaluate the components 
of the monoclonal protein (M protein). To obtain more information about 
the type of M protein present, tests for serum quantitative immunoglobulins 
as well as serum protein electrophoresis (SPEP) and serum immunofixation 
electrophoresis (SIFE) should be conducted. The assessment of changes in 
protein levels, particularly of the M protein, could help to track disease pro-
gression and response to treatment. Urine analysis should include 24-hour 
urine for total protein analyses, urine protein electrophoresis (UPEP) and 
urine immunofixation electrophoresis (UIFE). Along with SPEP and SIFE, 
a serum-free light chain assay has a high sensitivity in screening for MM and 
related plasma cell disorders. In addition, it has a prognostic value in plas-
ma cell disorders including MGUS, SMM, active myeloma, immunoglobulin 
light chain amyloidosis and solitary plasmacytoma.  
A bone marrow evaluation (including bone marrow immunohistochemistry 
and/or bone marrow flow cytometry) is recommended to detect quantitative 
and/or qualitative abnormalities of bone marrow plasma cells. A skeletal 
survey or a whole-body low-dose computed tomography (CT) to evaluate lyt-
ic bone lesions is recommended, as well as metaphase cytogenetics on bone 
marrow and plasma cell fluorescence in situ hybridisation (FISH). Addi-
tional diagnostic tests (useful in certain circumstances) recommended by the 
NCCN include a whole-body or skeletal magnetic resonance imaging (MRI) 
or whole-body positron emission tomography (PET)/CT scan, a tissue biop-
sy to diagnose a solitary osseous or extraosseous plasmacytoma, a plasma cell 
proliferation, the evaluation of serum viscosity, human leucocyte antigen 
(HLA) typing, an echocardiogram and the evaluation of light chain amyloi-
dosis [12]. 
Criteria for the diagnosis of MM are clonal bone marrow plasma cells ≥ 10% 
or plasmacytoma (extramedullary or of bone, proven by biopsy), and any one 
or more of the following events [8]: 
 Evidence of end organ damage that can be attributed to the under-
lying plasma cell proliferative disorder, specifically hypercalcaemia 
with serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the 
upper limit of normal or > 2.75 mmol/L (> 11 mg/dL), renal insuf-
ficiency with CrCl < 40 mL/min or serum creatinine > 177 μmol/L 
(> 2 mg/dL), anaemia with a haemoglobin value of > 20 g/L below 
the lower limit of normal or a haemoglobin value < 100 g/L, bone 
lesions with one or more osteolytic lesions on skeletal radiography, 
CT or PET/CT. 
 Any one or more of the following biomarkers of malignancy, includ-
ing ≥ 60% clonal bone marrow plasma cells, involved/uninvolved 
initially: medical history 
and physical 
examination 
 
 
 
various assessments are 
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serum-free light chain ratio ≥ 100, more than one focal lesion on 
MRI studies, where each focal lesion must be ≥ 5 mm. 
According to the International Staging System (ISS), based on the combina-
tion of serum levels of beta-2 microglobulin and albumin, three stages of 
MM can be distinguished, whereby ISS stage III is associated with the poor-
est outcome [8]: 
 ISS stage I: serum beta-2 microglobulin ≤ 3.5 mg/mL and serum al-
bumin ≥ 3.5 g/dL 
 ISS stage II: not stage I or III, 2 possibilities: serum beta-2 micro-
globulin < 3.5 mg/L but serum albumin < 3.5 g/dL or beta-2 mi-
croglobulin 3.5–5.5 mg/L, irrespective of the serum albumin 
 ISS stage III: serum beta-2 microglobulin ≥ 5.5 mg/mL. 
The revised International Staging System (R-ISS) includes data on the levels 
of serum beta-2 microglobulin, serum albumin and, additionally, serum 
LDH and a selected group of chromosomal abnormalities detected by FISH 
[8, 9]. 
Regarding the differential diagnosis of MM, the following conditions should 
be considered: MGUS, SMM, Waldenström’s macroglobulinaemia, solitary 
plasmacytoma, primary amyloidosis, POEMS syndrome (polyneuropathy, 
organomegaly, endocrinopathy, monoclonal protein, skin changes), and 
metastatic carcinoma [7]. 
 
 
 
6 Current treatment 
A0025: How is multiple myeloma currently managed according to published 
guidelines and in practice? 
The European Society for Medical Oncology (ESMO) recommends the two 
following treatment options for the front-line treatment of MM in elderly 
patients in the non-transplant setting (both approved in this setting by the 
EMA) [8]: 
 Bortezomib (given subcutaneously) + melphalan + prednisone 
(VMP) or 
 Lenalidomide + low-dose dexamethasone (Rd). 
Rd + Bortezomib (VRd) is another option for MM front-line treatment; 
nevertheless, this combination regimen is not yet approved by the EMA. 
Additional options for the treatment of newly diagnosed MM are melphalan 
+ prednisone + thalidomide (MPT, inferior to Rd in progression-free sur-
vival [PFS] and overall survival [OS]) or bortezomib + cyclophosphamide + 
dexamethasone (VCD), which is widely used (high response rates and pro-
longed PFS) although it is not approved by the EMA – due to a lack of con-
trol data. Other treatment options are cyclophosphamide + thalidomide + 
dexamethasone (CTD) and melphalan + prednisone (MP). A further treat-
ment option is bendamustine + prednisone, which is approved by the EMA 
in patients with clinical neuropathy at the time of diagnosis. 
ISS comprises  
3 stages 
revised ISS 
differential diagnosis 
ESMO recommends 
VMP or Rd for the front-
line treatment of MM in 
non-transplant setting 
other treatment options 
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The NCCN recommends the following therapies for the initial treatment of 
MM patients who are non-transplant candidates [12]: 
 Bortezomib + lenalidomide + dexamethasone or 
 Lenalidomide + low-dose dexamethasone or 
 Bortezomib + cyclophosphamide + dexamethasone. 
Other recommended regimens are carfilzomib + lenalidomide + dexame-
thasone, carfilzomib + cyclophosphamide + dexamethasone, and ixazomib 
+ lenalidomide + dexamethasone. The combination of bortezomib + dex-
amethasone is considered to be useful in certain circumstances [12].  
Since novel agents are available and accessible to patients in the US, the 
NCCN no longer considers melphalan-containing regimens as standard of 
care for the primary treatment of non-transplant candidates [12]. 
Of note, some of the regimens recommended by the NCCN are only ap-
proved in the US for the front-line treatment of MM. For example, carfil-
zomib + lenalidomide + dexamethasone, ixazomib + lenalidomide + dex-
amethasone are approved for the treatment of patients with MM, but only 
for those who have received at least one prior therapy. In Europe, the com-
bination regimen of bortezomib + lenalidomide + dexamethasone is not 
approved for the treatment of MM at all. 
 
 
 
7 Evidence 
A literature search was conducted on 4 April 2018 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “daratumumab”, “L01XC24”, “Darzalex”, “multiple 
myeloma”, “untreated”, “initial”, and “first-line”. Also, the manufacturer 
was contacted, who submitted five references (three of them had already 
been identified by systematic literature search). A manual search identified 
23 additional references (web documents and journal articles). 
Overall, 137 references were identified. Included in this report is one phase 
III study:  
 ALCYONE, a multicentre, randomised open-label study evaluating 
the efficacy and safety of the addition of daratumumab to the 
standard treatment of bortezomib, melphalan and prednisone for 
patients with untreated myeloma who are ineligible for SCT [13]. 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [14]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patients and treating physicians, selec-
tive outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 5 (see appendix). 
The external validity of the included trial was assessed using the EUnetHTA 
guideline on applicability of evidence in the context of a relative effective-
NCCN 
recommendations 
NCCN: melphalan-
containing regimens no 
longer standard of care  
systematic literature 
search in 5 databases:  
114 hits 
 
 
manual search: 23 
additional references 
overall: 137 references 
included: 1 study 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
applicability of  
study results 
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ness assessment of pharmaceuticals, considering the following elements: 
population, intervention, comparator(s), outcomes and setting [15]. 
The evaluation of the magnitude of “clinically meaningful benefit” that can 
be expected from a new anti-cancer treatment, the Magnitude of Clinical 
Benefit Scale developed by the European Society for Medical Oncology 
(ESMO-MCBS) was not applied, since it can only be used for the evaluation 
of solid tumours [16]. 
 
7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality cri-
teria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in 
clinical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence and amount of eligible 
patients correct? 
 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines as a method of quality assurance of scientific work. The 
final version and the policy recommendations are under full responsibility 
of the LBI-HTA. 
 
7.2 Clinical efficacy and safety –  
phase III study 
The ALCYONE trial [13, 17, 18] is a multicentre, randomised, open-label 
and active-controlled phase III trial evaluating the efficacy and safety of the 
addition of daratumumab to the standard combination treatment of borte-
zomib, melphalan and prednisone for MM. Between February 2015 and July 
2016, a total of 706 patients with newly diagnosed, documented MM who 
were ineligible for high-dose chemotherapy with stem-cell transplantation 
(due to coexisting conditions or an age of 65 years or older) were enrolled 
and randomised to either the daratumumab group (n = 350) or the control 
group (n = 356). The patients had a median age of 71 years (both groups); 
approximately one third of the patients were older than 75 years (29.7% of 
patients in the daratumumab group and 30.1% of patients in the control 
group). 52% of patients in the daratumumab group and 48.6% of the pa-
tients in the control group had an ECOG performance status of 1. The medi-
an time since MM was initially diagnosed was 0.8 months in patients of both 
ESMO-MCBS could  
not be assessed 
internal and external 
review  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
quality assurance 
method 
ALCYONE trial: 
randomised, open-label, 
multicentre phase III 
trial 
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groups. According to the International Staging System (ISS), 40.6% of pa-
tients in the daratumumab group and 36.2% of patients in the control group 
had disease stage III. 16.9% of patients in the daratumumab group and 
14.9% of patients in the control group had a high-risk cytogenetic profile. 
Detailed patient characteristics including inclusion and exclusion criteria 
can be found in Table 4. 
All patients received up to nine cycles (1 cycle = 42 days) of standard treat-
ment, including bortezomib (subcutaneous, 1.3 mg/m
2
 of body surface area, 
twice weekly on weeks 1, 2, 4 and 5 of cycle 1 and once weekly on weeks 1, 2, 
4 and 5 of cycles 2 through 9), melphalan (oral, 9 mg/m
2
, once daily on days 
1 through 4 of each cycle) and prednisone (oral, 60 mg/m
2
, once daily on 
days 1 through 4 of each cycle). Patients who were assigned to the daratu-
mumab group received daratumumab at a dose of 16 mg/kg of body weight 
(IV) once weekly in cycle 1, every 3 weeks in cycles 2 through 9 and every 
four weeks thereafter until disease progression or unacceptable toxicity. In 
addition, dexamethasone was administered orally or IV at a dose of 20 mg 
simultaneously to daratumumab to manage infusion reactions. Dexame-
thasone (20 mg) was substituted for prednisone on day 1 of each cycle. 
The primary endpoint of the ALCYONE trial was PFS, defined as the dura-
tion from the date of randomisation to either progressive disease or death, 
whichever came first. Key efficacy secondary endpoints were the overall re-
sponse rate (ORR), the rates of very good partial response or better (includ-
ing very good partial, complete and stringent complete responses), complete 
response (CR) or better (including complete and stringent complete re-
sponses), negative status for minimal residual disease (MRD, threshold of 1 
tumour cell per 10
5
 white cells) and OS. Other endpoints were safety, side-
effect profile, time to response and duration of response. 
The median duration of treatment was 14.7 months in patients of the dara-
tumumab group and 12 months in patients of the control group. At the clin-
ical cut-off date in June 2017, 79.8% of patients in the daratumumab group 
and 62.1% of control group patients had completed all nine cycles of stand-
ard treatment. Thereafter, patients of the control group discontinued treat-
ment and daratumumab group patients received further daratumumab 
monotherapy. The ALCYONE trial is ongoing, the estimated study comple-
tion date is 20 October 2021 [19]. Clinical efficacy data of the ALCYONE 
trial is presented in Table 1 and adverse events (AEs) are listed in Table 2. 
 
7.2.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of daratumumab on mortality? 
OS was a key efficacy secondary endpoint of the ALCYONE trial. At a me-
dian follow-up time of 16.5 months, 45 patients in the daratumumab group 
and 48 patients in the control group had died. In both groups, median OS 
was not reached.  
For long-term survival, follow-up is ongoing. According to the study proto-
col, long-term follow-up will continue until 330 deaths have been observed 
or five years after the last patient has been randomised, whichever is first 
[18].  
 
1 cycle = 42 days, 
patients received up to 9 
cycles of standard 
treatment 
 
 
daratumumab dose: 16 
mg/kg IV 
PFS: primary endpoint 
median duration of 
treatment: 14.7 months 
in the daratumumab 
group 
median OS was not 
reached in either group 
follow-up for long-term 
survival is ongoing 
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D0006: How does daratumumab affect progression (or recurrence) of multi-
ple myeloma? 
PFS was the primary endpoint of the ALCYONE trial; at the clinical cut-off 
date (12 June 2017) disease progression or death had occurred in 88 patients 
(25.1%) of the daratumumab group and in 143 (40.2%) patients of the con-
trol group. The hazard ratio (HR) for disease progression or death in the 
daratumumab group compared to the control group was 0.50 (95% confi-
dence interval [CI] 0.38–0.65; p < 0.001). The 12-month rate of PFS was 
86.7% (95% CI, 82.6–89.9) in patients of the daratumumab group versus 
76% (95% CI, 71.0–80.2) in patients of the control group. After 18 months, 
the rate of PFS was 71.6% (95% CI, 65.5–76.8) in the daratumumab group 
compared to 50.2% (95% CI, 43.2–56.7) in the control group. In the daratu-
mumab group, the median PFS was not reached (95% CI, could not be esti-
mated [NE]); in the control group, the median PFS was 18.1 months (95% 
CI, 16.5–19.9; p < 0.001). The superiority of the addition of daratumumab to 
the standard treatment with bortezomib, melphalan and prednisone was 
consistent across all pre-specified subgroups, including patients aged 75 
years or older and patients with a poor prognosis (ISS disease stage III, renal 
impairment or high-risk cytogenetic profile). 
 
D0005: How does daratumumab affect symptoms and findings (severity, fre-
quency) of multiple myeloma? 
Patients of the daratumumab group showed an ORR of 90.9% compared to 
73.9% in control group patients (p < 0.001). With 71.1% versus 49.7% (p < 
0.001) the rate of very good partial response (PR) or better was statistically 
significantly higher in daratumumab group patients than in control group 
patients. Also, the rate of CR or better was statistically significantly higher 
in the daratumumab group (42.6%) than in the control group (24.4%, p < 
0.001). In the daratumumab group, the rate of negative MRD status was 
more than three times as high as in the control group (22.3% vs. 6.2%, p < 
0.001). 
The median time to response among daratumumab group patients was 0.79 
months compared to 0.82 months in control group patients; the median time 
to best response was 4.9 months (daratumumab group) and 4.1 months (con-
trol group). In the daratumumab group, the median duration of response 
was not reached (95% CI, could not be estimated). In the control group, the 
median duration of response was 23.1 months (95% CI, 18.4–NE). 77.2% was 
the estimated percentage of patients who continued to have a response after 
18 months in the daratumumab group versus 60.4% in the control group. 
 
D0011: What is the effect of daratumumab on patients̕  body functions? 
Patients of the daratumumab group had a higher rate of grade 3 or 4 infec-
tions than patients of the control group (23.1% vs. 14.7%), the most common 
one was pneumonia (11.3% in the daratumumab group and 4% in the con-
trol group). 26.3% of daratumumab group patients had an upper respiratory 
tract infection (all grades) compared to 13.8% of control group patients. 
 
 
12-month PFS rate was 
86.7% with 
daratumumab vs. 76% 
in control group 
 
18-month PFS rate was 
71.6% with 
daratumumab vs. 50.2% 
in control group 
 
 
 
superiority of 
daratumumab in PFS 
was consistent across all 
subgroups 
ORR higher in 
daratumumab group 
(90.9% vs. 73.9%) 
 
statistically significant 
higher rate of very good 
PR or better and CR or 
better 
median time to 
response: 
daratumumab 0.79 
months 
 
control 0.82 months 
higher rate of grade 3 
and 4 infections in the 
daratumumab group 
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D0012: What is the effect of daratumumab on generic health-related quality 
of life? 
D0013: What is the effect of daratumumab on disease-specific quality of 
life? 
No evidence was found to answer these research questions as neither health-
related quality of life (HRQoL) nor quality of life (QoL) were endpoints of 
the present study. 
 
 
Table 1: Efficacy results of ALCYONE trial 
Descriptive statis-
tics and estimate 
variability 
Treatment group Daratumumab Control 
Number of patients 350 356 
PFS rate, % (95% CI) 
  at 12 months 
  at 18 months 
 
86.7 (82.6–89.9) 
71.6 (65.5–76.8) 
 
76.0 (71.0–80.2 
50.2 (43.2–56.7) 
Median PFS, months (95% CI) NR (NE) 18.1 (16.5–19.9) 
ORR rate, % 90.9 73.9 
Best OR, % 
  CR or better, % 
      Stringent CR 
      CR 
  Very good PR or better 
  Very good PR 
  PR 
  Stable disease 
  Progressive disease 
  Response could not be evaluated 
 
42.6 
18.0 
24.6 
71.1 
28.6 
19.7 
5.7 
0 
3.4 
 
24.4 
7.0 
17.4 
49.7 
25.3 
24.2 
21.3 
0.6 
4.2 
Negative status for MRD, % 22.3 6.2 
Median OS, months NR NR 
QoL NA NA 
Event of disease progression or death, % 21.5 40.2 
Median time to response, months 
Median time to best response, months 
Median duration of response, months (95% CI) 
0.79 
4.9 
NR (NE) 
0.82 
4.1 
21.3 (18.4–NE) 
Effect estimate per 
comparison 
Comparison groups 
Daratumumab 
vs. control 
Disease progression or death 
HR 0.50 
95% CI 0.38–0.65 
log-rank p-value < 0.001 
ORR* p-value < 0.001 
CR or better* p-value < 0.001 
Very good PR or better* p-value < 0.001 
Negative status for MRD§ p-value < 0.001 
Abbreviations: CI = confidence interval, CR = complete response, CRR = complete response rate, HR = hazard ratio, MRD = 
minimal residual disease, NA = not available, NE = could not be estimated, NR = not reached, OR = overall response, ORR = 
overall response rate, OS = overall survival, PFS = progression-free survival, PR = partial response, QoL = quality of life 
* ORR, CR or better and very good PR or better: p value was calculated by the use of the Cochran-Mantel-Haenszel chi-square 
test 
§ MRD: p value was calculated by the use of Fisher’s exact test 
HRQoL and QoL: no 
evidence 
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7.2.2 Safety 
 
C0008: How safe is daratumumab in relation to the comparator(s)? 
The most frequent AEs of any grade occurring in ≥ 20% of patients in either 
group were neutropenia (49.7% of daratumumab group patients vs. 52.5% of 
control group patients), thrombocytopenia (48.8% vs. 53.7%), peripheral 
sensory neuropathy (28.3% vs. 34.2%) and anaemia (28.0% vs. 37.6%), upper 
respiratory tract infection (26.3% vs. 13.8%), diarrhoea (23.7% vs. 24.6%), 
pyrexia (23.1% vs. 20.9%) and nausea (20.8% vs. 21.5%).  
The most common AEs of grade 3 or 4, occurring in ≥ 10% of patients in ei-
ther group, were haematologic AEs: neutropenia, thrombocytopenia and 
anaemia occurred in 39.9%, 34.4% and 15.9% of daratumumab group pa-
tients and in 38.7%, 37.6% and 19.8% of control group patients respectively.  
Infections of grade 3 or 4 were more frequent in patients receiving daratu-
mumab (23.1%) compared to control group patients (14.7%). The most 
common infection was pneumonia, occurring in 11.3% of daratumumab 
group patients and in 4% of control group patients. Owing to pneumonia of 
any grade, one patient in each group (0.3%) discontinued study treatment. 
Most infections resolved (in 87.9% of daratumumab group patients and 
86.5% of control group patients) and the rates of study treatment discontin-
uation due to infections were similar between the groups (0.9% in the dara-
tumumab group and 1.4% in the control group). Five patients (1.4%) of the 
daratumumab group died due to an infection: two patients died from pneu-
monia, one patient each died from peritonitis, septic shock and upper res-
piratory tract infection. In the control group, four patients (1.1%) died due 
to an infection, one patient each from septic shock, candida-related sepsis, 
bacterial pneumonia and sepsis. 14 patients (4%) of the daratumumab group 
and 16 patients (4.5%) of the control group died due to AEs that occurred 
within 30 days after the last trial treatment had been administered.  
The rate of serious AEs was 41.6% in daratumumab group patients and 
32.5% in control group patients; pneumonia was most common (10.1% of 
patients receiving daratumumab and 3.1% of control group patients). AEs 
led to discontinuation of study treatment in 4.9% of daratumumab group 
patients and 9% of control group patients. 27.7% of the patients receiving 
daratumumab experienced IRRs, mostly of grade 1 or 2 during the first in-
fusion. Most common IRRs were dyspnoea, chills, hypertension, pyrexia and 
bronchospasm. 4.3% of the patients had grade 3 IRRs, grade 4 IRRs oc-
curred in 0.6% of patients. Two patients (0.6%) in each group experienced a 
tumour lysis syndrome. A second primary cancer, which was pre-specified in 
the statistical analysis plan as an AE of clinical interest, has been diagnosed 
in 2.3% of daratumumab group patients and 2.5% of control group patients. 
 
C0002: Are the harms related to dosage or frequency of applying 
daratumumab? 
Concerning the tolerance of daratumumab in different dosing levels, data 
from a phase I/II, two-part trial, conducted in patients with relapsed mye-
loma or relapsed myeloma that was refractory to two or more prior lines of 
therapy is available [20]. In the dose- escalation part of the study, no maxi-
mum tolerated dose was found; at doses of 0.1 mg/kg and 1 mg/kg, dose-
most frequent AEs of 
any grade: neutropenia 
and thrombocytopenia 
most common AEs of 
grade 3 or 4: 
haematologic AEs 
infections were more 
frequent in patients 
receiving daratumumab, 
pneumonia was most 
common 
serious AEs in 41.6% 
(daratumumab group) 
and 32.5% (control 
group) 
 
27.7% of patients had 
IRRs 
 
 
second primary cancer 
in approx. 2.5% of 
patients 
studies comparing 
different dosages of 
daratumumab 
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limiting toxic effects were observed (grade 3 anaemia in 1 patient and grade 
3 elevation of the aspartate aminotransferase level in 1 patient, respectively). 
After three additional patients received daratumumab at these dose levels 
without showing dose-limiting toxic events, the dose level of daratumumab 
was safely increased to 24 mg/kg. Lonial et al. [21] assessed daratumumab in 
different dosages (8 mg/kg vs. 16 mg/kg) in a two-part phase II trial in pa-
tients with refractory MM. Analyses showed that the safety profile in the 8 
mg/kg group was similar to that in the 16 mg/kg group. Overall, daratu-
mumab was well tolerated; there were no treatment discontinuations due to 
drug-related treatment-emergent AEs, IRRs, or death.  
Xu et al. [22] conducted pharmacokinetic analyses using data from two trials 
[20, 21], showing that there was neither an apparent relationship between 
the peak concentration of daratumumab after the first dose (C
max, 1st
) and the 
occurrence of IRRs nor between the peak concentration after multiple doses 
(C
max
) and thrombocytopenia, anaemia, neutropenia, and lymphopenia. A 
numerically increase of the overall event rate with drug exposure was re-
ported which was not observed for grade three infections.   
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of daratumumab? 
Daratumumab should not be administered during pregnancy unless the 
benefit of the treatment to the patients is considered to outweigh the poten-
tial risks to the foetus. There is no evidence of the effect of daratumumab on 
newborns or infants. No information about potential effects of daratu-
mumab on the fertility of patients is available [2]. 
For patients with a history of chronic obstructive pulmonary disease 
(COPD), the use of short- and long-acting bronchodilators and inhaled cor-
ticosteroids after daratumumab infusions should be considered [2] to pre-
vent pulmonary complications (e.g. bronchospasm).  
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Table 2: ALCYONE trial: Most common adverse events during treatment in the safety population* 
 
AE (according to NCI CTCAE version 
4.0) 
 
Intervention (n = 346) Control (n = 354) 
 Any grade 
n (%) 
Grade 3 or 4 
n (%) 
Any grade 
n (%) 
Grade 3 or 4 
n (%) 
Haematologic AEs     
     Neutropenia 172 (49.7) 138 (39.9) 186 (52.5) 137 (38.7) 
     Thrombocytopenia 169 (48.8) 119 (34.4) 190 (53.7) 133 (37.6) 
     Anaemia 97 (28.0) 55 (15.9) 133 (37.6) 70 (19.8) 
Non-haematologic AEs     
     Peripheral sensory neuropathy 98 (28.3) 5 (1.4) 121 (34.2) 14 (4.0) 
     Diarrhoea 82 (23.7) 9 (2.6) 87 (24.6) 11 (3.1) 
     Pyrexia 80 (23.1) 2 (0.6) 74 (20.9) 2 (0.6) 
     Nausea 72 (20.8) 3 (0.9) 76 (21.5) 4 (1.1) 
     Infections 231 (66.8) 80 (23.1) 170 (48.0) 52 (14.7) 
            Upper respiratory tract infection 91 (26.3) 7 (2.0) 49 (13.8) 5 (1.4) 
            Pneumonia 53 (15.3) 39 (11.3) 17 (4.8) 14 (4.0) 
Secondary primary cancer 8 (2.3) NA 9 (2.5) NA 
Any infusion-related reaction 96 (27.7) 15 (4.3) NA NA 
Abbreviations: AE = adverse event, CTCAE = Common Terminology Criteria for Adverse Events, n = number, NA = not 
applicable, NCI = National Cancer Institute 
* Safety population = all patients who received at least one dose of trial treatment 
 
7.3 Clinical effectiveness and safety –  
further studies 
There are no further trials available assessing the addition of daratumumab 
to the standard combination regimen of bortezomib, melphalan and predni-
sone in patients with newly diagnosed MM who are not candidates for SCT. 
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of daratumumab? 
Daratumumab (Darzalex
®
) is available as a concentrate for solution for in-
fusion in vials of 100 mg at € 524 and 400 mg at € 2,096 (ex-factory prices) 
[23]. 
In the ALCYONE trial, daratumumab was administered at a dose of 16 
mg/kg of body weight once weekly in cycle one (1 cycle = 42 days), every 
three weeks in cycles 2 through 9 and every four weeks thereafter until dis-
ease progression or unacceptable toxicity [13]. 
no further trials are 
available  
100 mg = € 524 
400 mg = € 2,096 
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Based on the dosing regimen of the ALCYONE trial, the following costs for 
daratumumab treatment will incur: assuming an average body weight of 70 
kg, 1,120 mg of daratumumab per week are needed. One vial of concentrate 
for solution for infusion containing 400 mg costs € 2,096, resulting in € 6,288 
per week. Costs for the first cycle of daratumumab comprising six infusions 
are € 37,728. In cycles 2 to 9, when daratumumab is administered every 
three weeks, the costs for one cycle are € 12,576. In subsequent cycles, when 
daratumumab is administered every four weeks, one cycle costs € 9,432. The 
median treatment duration of ALCYONE trial patients was 14.7 months; as-
suming a cycle length of 42 days, 11 cycles of daratumumab treatment would 
be needed, costing approximately € 157,200.  
In addition, costs for the combination treatment with bortezomib, melpha-
lan and prednisone, as well as costs for concomitant pre- and post-infusion 
medication administered to reduce the risk of IRRs (including corticoster-
oids, antipyretics and antihistamines) incur.  
 
 
 
9 Ongoing research 
In April 2018, a search in databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu was conducted. The following phase III trials, 
assessing the use of daratumumab in patients with previously untreated 
MM, were identified: 
 NCT02541383: CASSIOPEIA, a randomised, open-label, multicen-
tre study to evaluate the use of daratumumab in combination with 
bortezomib, thalidomide and dexamethasone in transplant-eligible 
patients with previously untreated MM. Estimated study comple-
tion date is August 2024. 
 NCT03301220: An open-label, multicentre study to assess whether 
daratumumab (administered subcutaneously) compared with active 
monitoring prolongs PFS in patients with high-risk SMM. Estimat-
ed study completion date is December 2025. 
 NCT02252172: MAIA, a randomised, open-label trial comparing 
daratumumab, lenalidomide and dexamethasone versus lenalido-
mide and dexamethasone in patients with previously untreated MM 
who are not candidates for high-dose chemotherapy and autologous 
stem-cell transplantation. Estimated study completion date is No-
vember 2024. 
 NCT03217812: A randomised, open-label, multicentre, controlled 
study comparing bortezomib, melphalan and prednisone to dara-
tumumab, bortezomib, melphalan and prednisone in patients with 
previously untreated MM who are ineligible for high-dose chemo-
therapy. Estimated study completion date is October 2022. 
There are numerous phase I and phase II studies ongoing, evaluating the ef-
ficacy and safety of daratumumab-only or combination regimens including 
daratumumab in patients with previously untreated MM as well as in pa-
tients with relapsed and refractory MM.  
costs for cycle 1:  
€ 37,728 
costs for 1 cycle of cycles 
2–9: € 12,576 
costs for 1 cycle beyond 
cycle 9: € 9,432 
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duration of the 
daratumumab group 
was 14.7 months 
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10 Discussion 
Daratumumab (Darzalex
®
) is a human monoclonal IgG1κ antibody directed 
against CD38 [2]. It is approved by the EMA and the FDA as a monotherapy 
or in combination regimens for patients with MM who received prior lines 
of therapy [4, 5]. In May 2018, the FDA approved daratumumab in combi-
nation with bortezomib, melphalan and prednisone for the treatment of pa-
tients with newly diagnosed MM who are ineligible for ASCT, whereas dara-
tumumab is not approved by the EMA for the assessed indication. 
The ALCYONE trial [13] investigated the efficacy and safety of the addi-
tion of daratumumab to bortezomib, melphalan and prednisone in patients 
with newly diagnosed MM who were ineligible for high-dose chemothera-
py with SCT. Analyses showed that patients of the daratumumab group 
had a lower risk of disease progression or death than patients of the con-
trol group: HR was 0.50 (95% CI, 0.38–0.65; p < 0.001). The 12-month rate 
and the 18-month rate of PFS were prolonged in patients receiving dara-
tumumab (86.7% and 71.6% respectively) compared to control group pa-
tients (76.0% and 50.2% respectively). For PFS, the superiority of the ad-
dition of daratumumab to bortezomib, melphalan and prednisone was 
consistent across all pre-specified subgroups, including patients with a 
poor prognosis or patients of 75 years or older. The ORR was higher in the 
daratumumab group (90.9%) than in the control group (73.9%); the rates 
of very good PR or better and the rate of CR or better were statistically 
significantly higher in patients receiving daratumumab than in control 
group patients: 71.1% vs. 49.7% and 42.6% vs. 24.4% respectively. Also, 
the rate of negative status for MRD was more than three times as high in 
the patients of the daratumumab group (22.3%) as in the patients of the 
control group (6.2%).  
The median duration of response was 21.3 months in the control group, 
whereas it was not reached in the daratumumab group. The median OS 
was not reached in either group. At a median follow-up of 16.5 months, 
death had occurred in 45 of 350 patients in the daratumumab group and in 
48 of 356 patients in the control group. Although the ALYCONE trial is 
ongoing until October 2021, no valid follow-up data for long-term survival 
can be expected, owing to the fact that all patients in the control group dis-
continued treatment after nine cycles whereas all patients in the daratu-
mumab group received further daratumumab as monotherapy. Neither is 
any data available regarding the QoL of the study patients. 
The most frequent AEs of grade 3 or 4 were neutropenia, thrombocytopenia 
and anaemia, occurring in 39.9%, 34.4% and 15.9% of daratumumab group 
patients and in 38.7%, 37.6% and 19.8% of control group patients respec-
tively. The rate of grade 3 or 4 infections (most commonly pneumonia) was 
higher in patients receiving daratumumab (23.1%) than in patients of the 
control group (14.7%); however, the rate of discontinuation of trial treat-
ment due to infection was similar between the two groups (0.9% in the dara-
tumumab group vs. 1.4% in the control group). The rate of serious AEs was 
higher in patients receiving daratumumab (41.6%) than in control group pa-
tients (32.5%). Of the patients receiving daratumumab, 27.7% experienced 
IRRs, mostly during the first infusion. 4.3% and 0.6% of daratumumab 
group patients had grade 3 and grade 4 IRRs respectively. 
assessed indication: 
approved by the FDA, 
not approved by the 
EMA 
ALCYONE trial, 
daratumumab group: 
 
50% lower risk of 
disease progression or 
death 
 
statistically significantly 
longer PFS, higher ORR 
rate 
 
statistically significantly 
higher rates of very 
good PR or better and 
CR or better 
 
higher rate of negative 
status for MRD 
median OS was not 
reached in either group 
 
trial ongoing, QoL not 
assessed 
 
no valid OS data 
expectable  
most frequent AEs were 
haematologic 
 
 
 
 
 
higher rates of serious 
AEs in the 
daratumumab group 
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In terms of safety, the higher rate of grade 3 or 4 infections among patients 
receiving daratumumab is worth mentioning, as is the higher rate of serious 
AEs. Interestingly, these facts did not lead to a higher rate of study treat-
ment discontinuation. Despite the administration of pre-infusion medica-
tion, approximately one third of daratumumab group patients experienced 
IRRs.  
The external and internal validity of the ALCYONE trial is compromised by 
methodological limitations. ALCYONE was conducted as an open-label 
study; both the patients and the treating physicians were unmasked to 
treatment assignment, which may lead to a performance and/or detection 
bias. As the trial is currently ongoing, not all of the pre-specified endpoints 
from the protocol have been reported yet. However, a high risk of bias could 
be detected due to the open-label, unblinded study design and other aspects 
that may increase the risk of bias. Regarding the external validity it is no-
ticeable that – with a cycle length of 42 days – the dosing schedule used in 
the ALCYONE trial differs from the approved dosing regimens [2] as well as 
from dosing regimens used in other trials [24, 25] with a usual cycle length 
of 21 or 28 days respectively.  
There are studies indicating the efficacy and safety of the addition of dara-
tumumab to treatment regimens including lenalidomide plus dexame-
thasone (POLLUX trial [24]) or bortezomib plus dexamethasone (CASTOR 
trial [25]). However, these trials assessed three-drug regimens; included pa-
tients that had relapsed or relapsed and refractory MM and had received at 
least one prior treatment. ALCYONE was the first trial that investigated 
daratumumab for the front-line treatment of MM and there is no further 
study available to confirm the results of the ALCYONE trial with the ad-
ministered four-drug regimen. Therefore, the results of an ongoing random-
ised, open-label, multicentre, controlled study comparing bortezomib, mel-
phalan and prednisone to daratumumab, bortezomib, melphalan and pred-
nisone in patients with previously untreated MM who are ineligible for 
high-dose chemotherapy (NCT03217812), conducted in the Asia Pacific re-
gion, will be of high interest. Likewise, the results from the MAIA trial 
(NCT02252172), comparing daratumumab, lenalidomide and dexame-
thasone with lenalidomide and dexamethasone in patients with previously 
untreated MM, may yield more evidence. Particularly in view of the fact that 
the NCCN no longer considers melphalan-containing regimens as standard 
of care for the primary treatment of transplant-ineligible MM patients in the 
US [12], the investigation of daratumumab in combination with a different 
backbone regimen might also be useful. 
According to the dosing regimen used in the ALCYONE trial, the costs of 
daratumumab are € 37,728 for the first cycle, € 12,576 in cycles 2 to 9 and € 
9,432 in subsequent cycles [13, 23]. Patients of the ALCYONE trial had a 
median treatment duration of 14.7 months. Assuming a cycle length of 42 
days, 11 cycles of daratumumab treatment would be needed, costing approx-
imately € 157,200. Additionally, costs for the standard treatment with borte-
zomib, melphalan and prednisone incur. Costs increase by the administra-
tion of required concurrent medication to reduce the risk of IRRs, including 
corticosteroids, antipyretics and antihistamines.  
higher infection rates 
did not lead to 
discontinuation 
high risk of bias 
 
 
 
 
 
 
limited external 
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more data in this special 
setting is needed 
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the front-line setting 
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The addition of daratumumab to the standard combination treatment of 
bortezomib, melphalan and prednisone in untreated MM patients resulted 
in a statistically significant benefit with a lower risk of disease progression 
or death, prolongation of PFS across all subgroups and a higher rate of nega-
tive status for MRD. These benefits need to be weighed against higher rates 
of infections and the occurrence of IRRs among patients receiving daratu-
mumab. Furthermore, the costs for a four-drug regimen and the required 
concurrent medication have to be considered. Since no further valid OS data 
can be expected and QoL data is lacking, the clinical benefit of the assessed 
intervention remains to be proven. Finally, more robust evidence, particu-
larly for the use of daratumumab for the front-line treatment of MM is 
needed; as well as the investigation of appropriate and feasible combination 
regimens. 
daratumumab provides 
a benefit  
 
lack of QoL and OS data 
 
 
robust evidence in 
different settings is 
required 
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12 Appendix  
Table 3: Administration and dosing of daratumumab (Darzalex
®
) [2, 13, 23] 
 Technology Comparator 
Administration mode Intravenous infusion (IV) 
No active compara-
tor is available 
Description of packaging 
Darzalex® is a concentrate for solution for infusion and is a col-
ourless to yellow liquid. It is supplied as a carton pack containing 
1 glass vial. One mL of concentrate contains 20 mg daratu-
mumab. Each vial of 5 mL concentrate contains 100 mg of dara-
tumumab. Each vial of 20 mL concentrate contains 400 mg of 
daratumumab. 
Total volume contained in packag-
ing for sale 
Darzalex® concentrate for solution for infusion 100 mg 
Darzalex® concentrate for solution for infusion 400 mg 
Dosing 
ALCYONE trial: 16mg/kg (IV) of body weight of daratumumab, 
once weekly in cycle 1, every 3 weeks in cycles 2 through 9 and 
every 4 weeks thereafter until disease progression or unac-
ceptable toxic effects. 
Median treatment duration 
Median duration of treatment with daratumumab in patients 
participating in the ALCYONE trial was 14.7 months. 
Contraindications 
Hypersensitivity to the active substance or to any of the excipi-
ents (glacial acetic acid, mannitol (E421), polysorbate 20, sodi-
um acetate trihydrate, sodium chloride, water for injections). 
Drug interactions 
No interaction studies have been performed. 
 
As an IgG1κ monoclonal antibody, renal excretion and hepatic 
enzyme-mediated metabolism of intact daratumumab are un-
likely to represent major elimination routes. As such, variations 
in drug-metabolising enzymes are not expected to affect the 
elimination of daratumumab. Due to the high affinity to a 
unique epitope on CD38, daratumumab is not anticipated to al-
ter drug-metabolising enzymes. 
 
Clinical pharmacokinetic assessments of pomalidomide, thalid-
omide and bortezomib indicated no clinically relevant drug-drug 
interaction between daratumumab and these combination ther-
apies. 
 
Interference with indirect antiglobulin test (indirect Coombs 
test): daratumumab binds to CD38 on RBCs and interferes with 
compatibility testing, including antibody screening and cross 
matching. Daratumumab interference mitigation methods in-
clude treating reagent RBCs with DTT to disrupt daratumumab 
binding or other locally validated methods. Since the Kell blood 
group system is also sensitive to DTT treatment, Kell-negative 
units should be supplied after ruling out or identifying alloanti-
bodies using DTT-treated RBCs. Alternatively, phenotyping or 
genotyping may also be considered. 
 
Interference with SPE and IFE tests: daratumumab may be de-
tected on SPE and IFE assays used for monitoring disease mono-
clonal immunoglobulins (M proteins). This can lead to false-
positive SPE and IFE assay results for patients with IgG kappa 
myeloma protein impacting initial assessment of complete re-
sponses by IMWG criteria. In patients with persistent very good 
partial response other methods to evaluate the depth of re-
sponse should be considered. 
Abbreviations: DTT = dithiothreitol, IMWG = International Myeloma Working Group, IFE = immunofixation electrophoresis, Ig = immuno-
globulin, IV = intravenous, RBCs = red blood cells, SPE = serum protein electrophoresis  
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Table 4: Characteristics of the ALCYONE trial 
Title: Daratumumab plus bortezomib, melphalan and prednisone for untreated myeloma [13, 17, 18] 
Study identifier NCT02195479, EudraCT number: 2014-002272-88, ALCYONE trial 
Design Multicentre, randomised, open-label, active-controlled phase III trial 
Duration of main phase: Enrolment: 9 February 2015 to 14 July 2016 
 Clinical cut-off date: 12 June 2017 
 Median follow-up: 16.5 months 
Hypothesis 
  
Superiority    
                 
A sample size of 350 patients per group (under the assumption of an annual dropout rate of 5%) was es-
timated to provide 80% power to detect a 27% lower risk of disease progression or death in the daratu-
mumab group than in the control group, with the use of a log-rank test with a two-sided alpha level of 
0.05. The primary efficacy end point was estimated with the Kaplan-Meier method, and the treatment ef-
fect (HR) and its two-sided 95% confidence interval were estimated with a stratified Cox regression mod-
el. Statistical significance was evaluated with a stratified log-rank test based on the predetermined alpha 
level at the clinical cut-off date.     
                                                                                                                                                 
Funding Janssen Research and Development 
Treatments groups 
 
Intervention (n = 350) 
Patients received up to nine (42-day) cycles of subcutaneous borte-
zomib (1.3 mg/m2 of body surface area, twice weekly on weeks 1, 2, 
4 and 5 of cycles 2 through 9), oral melphalan (9 mg/m2, once daily 
on days 1 through 4 of each cycle) and oral prednisone (60 mg/m2, 
once daily on days 1 through 4 of each cycle). 
Daratumumab (IV) at a dose of 16 mg/kg of body weight was ad-
ministered with dexamethasone (oral or IV) at a dose of 20 mg 
once weekly in cycle 1, every 3 weeks in cycles 2 through 9 and eve-
ry 4 weeks thereafter until disease progression or unacceptable 
toxic effects. Dexamethasone (20 mg) was substituted for predni-
sone on day 1 of each cycle. 
Control (n = 356) 
Patients received up to nine (42-day) cycles of subcutaneous borte-
zomib (1.3 mg/m2 of body surface area, twice weekly on weeks 1, 2, 
4 and 5 of cycles 2 through 9), oral melphalan (9 mg/m2, once daily 
on days 1 through 4 of each cycle) and oral prednisone (60 mg/m2, 
once daily on days 1 through 4 of each cycle). 
Endpoints and definitions 
 
Progression-free survival 
(primary endpoint) PFS Time from randomisation to either disease progression or death. 
Overall response rate (key 
efficacy secondary end-
point) 
ORR 
The proportion of patients who achieved PR or better, according to 
the International Myeloma Working Group criteria, during or after 
the study treatment. 
Complete response rate 
(key efficacy secondary 
endpoint) 
CRR 
Defined as the percentage of patients achieving CR, as defined by a 
negative immunofixation of serum and urine, the disappearance of 
any soft-tissue plasmacytomas and < 5% plasma cells in the bone 
marrow. For those patients with a negative or low serum protein 
electrophoresis (≤ 0.2 g/L) and suspected daratumumab interfer-
ence on immunofixation, a reflex assay with anti-idiotype antibody 
was used to confirm daratumumab interference and rule out a 
false-positive immunofixation. Patients who had confirmed dara-
tumumab interference but met all other clinical criteria for strin-
gent CR or CR were considered to have achieved stringent CR or 
CR. 
Minimal residual disease 
(MRD) negativity rate 
(key efficacy secondary 
endpoint) 
- 
The proportion of patients who were negative for MRD at any time 
point after randomisation (at a threshold of 1 tumour cell per 105 
white cells). 
Overall survival (key effi-
cacy secondary endpoint) 
OS The time from randomisation to the date of the patient’s death.  
Time to response - The time between randomisation and the first efficacy evaluation in which the patients had met all criteria for PR or better. 
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Title: Daratumumab plus bortezomib, melphalan and prednisone for untreated myeloma [13, 17, 18] 
Study identifier NCT02195479, EudraCT number: 2014-002272-88, ALCYONE trial 
Duration of response - 
Calculated from the date of initial documentation of a response 
(PR or better) to the date of the first documented evidence of pro-
gressive disease, as defined by the International Myeloma Working 
Group criteria. 
Database lock Clinical cut-off date: 12 June 2017 
Results and analysis  
Analysis description Primary analysis 
The primary analysis population was the intention-to-treat population of all the patients who underwent 
randomisation. The safety population comprised patients who received any dose of initial treatment. 
Of two planned interim analyses, the first evaluated only safety after 100 patients had received at least 
two treatment cycles or had discontinued treatment. The second (reported here) assessed safety and effi-
cacy when 231 events of disease progression or death had occurred. The final overall survival analysis will 
occur after 330 deaths. 
Analysis population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion 
 Patients with newly diagnosed, documented MM 
 Not eligible for high-dose chemotherapy with stem-cell 
transplantation owing to coexisting conditions or an age 
of ≥ 65 years  
 Haemoglobin level of ≥ 7.5 g/dL 
 Absolute neutrophil count of ≥ 1.0x109/L 
 Aspartate aminotransferase and alanine aminotransfer-
ase levels of 2.5 or fewer times the upper limit of the 
normal range 
 Total bilirubin level of 1.5 or fewer times the upper limit 
of the normal range 
 Creatinine clearance of ≥ 40 mL/min 
 Corrected serum calcium level of ≤ 14 mg/dL (≤ 3.5 mmol 
per litre) 
 Platelet count of ≥ 70x109/L (if < 50% of bone marrow 
nucleated cells were plasma cells; otherwise, platelet 
count of > 50x109/L) 
 ECOG performance status of 0 to 2 
 
Exclusion 
 Patients with primary amyloidosis, monoclonal gammo-
pathy of undetermined significance, smouldering MM, 
Waldenström’s macroglobulinaemia (or other conditions 
in which IgM paraprotein is present in the absence of a 
clonal plasma cell infiltration with lytic bone lesions 
 Previous systemic therapy or stem-cell transplantation 
 Cancer within 3 years before randomisation (exceptions 
were squamous-cell and basal-cell carcinomas of the 
skin, carcinoma in situ of the cervix, and any cancer that 
was considered to be cured with minimal risk of recur-
rence within 3 years) 
 Peripheral neuropathy, or grade 2 or higher neuropathic 
pain (as defined by the NCI CTCAE version 4.0) 
Characteristics Intervention  (n = 350)  
Control 
(n = 356) 
Median age (range), years 
Distribution, n (%) 
    < 65 years 
    65–74 years 
    ≥ 75 years 
71.0 (40–93) 
 
36 (10.3) 
210 (60.0) 
104 (29.7) 
71.0 (50–91) 
 
24 (6.7) 
225 (63.2) 
107 (30.1) 
Male, n 
Female, n 
160 
190 
167 
189 
Race, n (%) 
    White  
    Black 
    Asian 
    Other or unreported 
 
297 (84.9) 
3 (0.9) 
47 (13.4) 
3 (0.9) 
 
304 (85.4) 
3 (0.8) 
45 (12.6) 
4 (1.1) 
ECOG performance status, n (%) 
    0 
    1 
    2 
 
78 (22.3) 
182 (52.0) 
90 (25.7) 
 
99 (27.8) 
173 (48.6) 
84 (23.6) 
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Title: Daratumumab plus bortezomib, melphalan and prednisone for untreated myeloma [13, 17, 18] 
Study identifier NCT02195479, EudraCT number: 2014-002272-88, ALCYONE trial 
Analysis population 
(continuation) 
Type of measurable disease, n (%) 
   IgG 
   IgA 
   Other (including IgD, IgM, IgE,  
   and biclonal) 
   Detected in serum and urine 
   Detected in urine only 
   Detected in serum-free light chains 
   only 
 
143 (40.9) 
49 (14.0) 
 
6 (1.7) 
91 (26.0) 
43 (12.3) 
 
18 (5.1) 
 
140 (39.3) 
53 (14.9) 
 
3 (0.8) 
105 (29.5) 
37 (10.4) 
 
18 (5.1) 
ISS disease staging, n (%) 
   I 
   II 
   III 
 
69 (19.7) 
139 (39.7) 
142 (40.6) 
 
67 (18.8) 
160 (44.9) 
129 (36.2) 
Cytogenetic profile, n (%) 
   Standard-risk cytogenetic abnormality 
   High-risk cytogenetic abnormality 
 
261/314 (83.1) 
53/314 (16.9) 
 
257/302 (85.1) 
45/302 (14.9) 
Median time since initial diagnosis of 
MM, months (range) 
 
0.76 (0.1–11.4) 
 
0.82 (0.1–25.3) 
Applicability of evidence 
Population 
The ALCYONE trial included patients (median age 71.0 years) with newly diagnosed MM who were not el-
igible for high-dose chemotherapy with stem-cell transplantation. Approximately one third of the patients 
were older than 75 years. The majority of patients had an ECOG performance status of 1, a standard-risk 
cytogenetic profile and ISS disease stage of II or III.  
Intervention 
The administration of daratumumab in the ALCYONE trial differs from the approved dosing schedule, 
since one treatment cycle (usually comprising 21 or 28 days) comprises 42 days. The mode of administra-
tion and the dosing of daratumumab are consistent with the approved license. All patients of the control 
group discontinued treatment after nine cycles and all patients of the daratumumab group continued 
daratumumab as monotherapy. 
Comparators 
There is currently no data available comparing daratumumab to another drug in this special setting. The 
results of NCT03217812, comparing bortezomib, melphalan and prednisone to daratumumab, bortezomib, 
melphalan and prednisone in patients with previously untreated MM who are ineligible for high-dose 
chemotherapy, and the results of the MAIA trial (NCT02252172), comparing daratumumab, lenalidomide 
and dexamethasone versus lenalidomide and dexamethasone in patients with previously untreated MM 
who are not candidates for high-dose chemotherapy and autologous stem-cell transplantation are awaited 
for October 2022 and November 2024 respectively. 
Outcomes 
There is evidence that the addition of daratumumab to the standard treatment of bortezomib, melphalan 
and prednisone results in a lower risk of disease progression or death, prolongation of PFS and higher 
rates of negative status for MRD. Since the ALCYONE trial is ongoing, no data regarding long-term sur-
vival is available yet; QoL of patients has been not assessed in the ALCYONE trial. Patients receiving dara-
tumumab have shown higher rates of grade 3 and 4 infections; approximately one third of daratumumab 
group patients have experienced IRRs. 
Setting 
The ALCYONE trial is a multicentre study (162 sites in 25 countries across North and South America, Eu-
rope and the Asia-Pacific region) funded by Janssen Research and Development. 
Abbreviations: CR = complete response, CRR = complete response rate, CTCAE = Common Terminology Criteria for Adverse Events, ECOG = Eastern 
Cooperative Oncology Group, HR = hazard ratio, Ig = immunoglobulin, ISS = International Staging System, IV = intravenous, MM = multiple myeloma, 
MRD = minimal residual disease, n = number, NCI = National Cancer Institute, ORR = overall response rate, PFS = progressive-free survival, PR = partial 
response 
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Table 5: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [14] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: Patients were randomly assigned by means 
of an interactive Web-response system in a 1:1 ratio 
Yes 
Adequate allocation concealment: Web-based randomisation system has been used 
 
Yes 
Blinding  
 
Patient: open-label No 
Treating physician: open-label No 
Selective outcome reporting unlikely: Not all of the pre-specified endpoints from the protocol 
have been reported yet; however, the trial is still ongoing. Reasons for discontinuations have 
been reported. 
Unclear 
No other aspects which increase the risk of bias: Janssen Research and Development are 
sponsoring the trial and designed it in collaboration with the academic authors; data has been 
compiled and maintained by the sponsor. 
No 
Risk of bias – study level High-risk 
 
